Correlation Between PET and Advanced MRI in Multiple Sclerosis
NCT ID: NCT02869360
Last Updated: 2019-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
14 participants
OBSERVATIONAL
2016-10-31
2019-10-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This pilot study is an opportunity to determine the relationship between quantitative advanced MRI measures and OCT with PET measurements of microglial activation and myelin health.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Imaging in Demyelinating Diseases
NCT05805839
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
NCT00321568
Natural History of Multiple Sclerosis and Its Mimickers
NCT02504840
Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders
NCT02836327
Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis
NCT00099307
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Multiple Sclerosis (MS) patients
4 Secondary Progressive MS patients on no disease modifying therapy 4 Primary Progressive MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on no disease modifying therapy 4 Relapsing-Remitting MS patients on Glatiramer Acetate 40 mg three times a week
No interventions assigned to this group
Healthy Controls
4 Healthy volunteers aged between 18-60 years of age
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 to 60
* High or mixed affinity binder to rs6971 TSPO polymorphism
Exclusion Criteria
* Suffering from an unstable medical condition
* Have a neurological or ocular disorder other than MS
* Any contra-indications to MRI
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Teva Pharmaceuticals USA
INDUSTRY
University of British Columbia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Philippe Beauchemin
Clinical Fellow
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
MS Clinical Trials Group - UBC
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNS-2016-293
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.